Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Ensysce Biosciences (ENSC) EBT Margin (2020 - 2025)

Historic EBT Margin for Ensysce Biosciences (ENSC) over the last 6 years, with Q3 2025 value amounting to 759.97%.

  • Ensysce Biosciences' EBT Margin fell 7787100.0% to 759.97% in Q3 2025 from the same period last year, while for Sep 2025 it was 246.43%, marking a year-over-year decrease of 669900.0%. This contributed to the annual value of 153.94% for FY2024, which is 3424500.0% up from last year.
  • According to the latest figures from Q3 2025, Ensysce Biosciences' EBT Margin is 759.97%, which was down 7787100.0% from 127.87% recorded in Q2 2025.
  • Over the past 5 years, Ensysce Biosciences' EBT Margin peaked at 18.74% during Q3 2024, and registered a low of 3418.77% during Q2 2022.
  • Moreover, its 5-year median value for EBT Margin was 467.7% (2023), whereas its average is 764.75%.
  • Its EBT Margin has fluctuated over the past 5 years, first plummeted by -31211600bps in 2022, then surged by 29510700bps in 2023.
  • Over the past 5 years, Ensysce Biosciences' EBT Margin (Quarter) stood at 123.48% in 2021, then plummeted by -253bps to 436.19% in 2022, then crashed by -56bps to 679.66% in 2023, then skyrocketed by 60bps to 275.17% in 2024, then crashed by -176bps to 759.97% in 2025.
  • Its EBT Margin stands at 759.97% for Q3 2025, versus 127.87% for Q2 2025 and 149.37% for Q1 2025.